with the heavier transition metal rhodium.
How is Sunko and colleagues' discovery possible if cobalt is such a lightweight? The key turns out to be an unusual form of ISB. The structure of PtCoO 2 terminates with a sandwich of oxygen-cobalt-oxygen layers at the surface (Fig. 1) . Although the conduction electrons derive from cobalt atoms, they cannot jump directly between these atoms because the interatomic distance is too large. Instead, they flow along one of two zigzagging routes between cobalt and oxygen layers. For the electrons, these routes are not equivalent because they are at different distances from the surface. Imagine a two-lane road adjacent to a cliff -even if the lanes are identical, traffic might go more slowly in the lane closer to the edge because drivers are distracted by the view. The substantial asymmetry of the electrons' conduction pathways is a dramatic manifestation of ISB.
According to the authors, in ordinary materials, spin-momentum coupling is typically limited by the smaller energy scale of ISB with respect to that of SOC. Increasing the atomic weight of the material, and consequently the magnitude of SOC, therefore provides diminishing returns. By contrast, the unusually large magnitude of ISB in PtCoO 2 unlocks the full atomic SOC of cobaltwhich is not so weak, after all, contrary to conventional wisdom.
Sunko and colleagues' study draws a striking contrast between two distinct regimes of the Rashba effect that are characterized by the relative magnitudes of SOC and ISB. Moreover, it is unusual to observe SOC effects in d-electron systems such as PtCoO 2 . In these systems, the localized nature of the electrons makes them susceptible to electron correlation effects -leading to phenomena such as high-temperature superconductivity in other transition-metal oxides [7] [8] [9] . The coexistence of the Rashba effect and correlation effects in PtCoO 2 makes the material a fascinating playground for exploring new, potentially exotic physics.
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CANCER

Bad blood promotes tumour progression
Mutations that drive the abnormal expansion of progenitor subpopulations of blood cells are known to cause leukaemia. A genetic analysis reveals that these clonal blood stem-cell mutations are also common in people who have solid tumours.
C AT R I O N A J A M I E S O N
T he acquisition of mutations in bloodforming (haematopoietic) stem cells can lead to a process called clonal haematopoiesis, in which subpopulations of mutant blood cells arise. This phenomenon can be a treacherous contributor to the progression of leukaemia and death. Writing in Cell Stem Cell, Coombs et al. 1 provide evidence that clonal haematopoiesis is also common in people who have solid tumours. In these people, the phenomenon is associated with increased age, tobacco use and radiation therapy, is correlated with an increased risk of leukaemia, and is linked to reduced overall survival.
The idea of clonal haematopoiesis dates back to 1960, when a chromosomal abnormality in blood cells was first associated with cancer 2 -specifically, with chronic myeloid leukaemia (CML). Subsequently, evidence emerged 3 that the bone-marrow disorder polycythaemia vera (which, like CML, involves enhanced proli feration of blood cells) derives from defective haematopoietic stem cells (HSCs). Studies in mice [4] [5] [6] pinned down the functional impact of specific mutations involved in these diseases, and analysis 7, 8 of patient-derived bone marrow confirmed that the mutations identified in mice also arise in human HSCs. Cumulatively, these studies proved that both pre-leukaemic disorders (such as myeloproliferative neoplasms and myelodysplastic syndrome) and leukaemia itself can arise from clonal haematopoiesis.
More recently, an analysis 9 of the proteincoding DNA of 17,182 people demonstrated that clonal haematopoiesis occurs with ageing. The study revealed that variants in three genes (DNMT3A, TET2 and ASXL1) occurred in the blood cells of more than 9.5% of individuals older than 70. These variants conferred a higher risk of leukaemia, coronary heart disease, stroke and death. But this work, although seminal, did not address a possible relationship between clonal haematopoiesis and solid tumours.
To investigate the possibility of such a link, Coombs et al. sequenced matched blood and tumour samples from 8,810 individuals with solid tumours. In particular, they analysed the protein-coding sequences of either 341 or 410 cancer-associated genes, with more genes being analysed in patients enrolled later in the study. This revealed clonal haematopoiesis in 25.1% of people with solid tumours. About 4.5% of them had mutations previously shown to promote leukaemia, including those in the genes TP53 and PPM1D. These mutations were associated with exposure to chemotherapy, an increased rate of leukaemia and lower survival rates.
The authors followed the progress of 5,394 of the patients for between 12 and 21 months. Notably, 19 individuals developed some form of blood cancer after the matched blood and tumour samples were taken. The likelihood of this occurring was statistically higher for patients who had clonal haematopoiesis, thereby underscoring the impact of this phenomenon on both cancer initiation and progression.
Strikingly, the cause of death in 98% of the patients who died during the study was solidtumour progression. Together, then, Coombs and colleagues' findings demonstrate that the risk of a cancer progressing is higher if an individual carries a mutation that causes , reported on pages 528 and 482, respectively.
Animal studies and epidemiological analysis in humans have shown that if a mother is infected by certain viruses during pregnancy, there is a risk that her offspring will develop autism or other neurodevelopmental disorders 3, 4 . This phenomenon is often studied using a mouse model in which viral infection is mimicked by exposing pregnant animals to a synthetic molecule called poly(I:C) that is structurally similar to double-stranded RNA, a common hallmark of viral infection (Fig. 1) . This exposure triggers an immune response in the mother that is termed maternal immune activation (MIA), which can lead to atypical social and repetitive behaviours in her offspring 5 . However, the molecular and cellular basis for this phenomenon has remained poorly understood until now.
In a previous study 5 , Kim, Yim and their colleagues used this mouse model of MIA to show that interleukin 17a (IL-17a), a protein secreted into the pregnant mother's bloodstream, is required for the behavioural abnormalities to develop in offspring. The authors also found that IL-17a is secreted by maternal immune cells called T helper 17 (T H 17) cells.
Kim et al. now reveal key missing links in the process that activates this T H 17-cell immune response in mothers. First, they found that IL-17a secretion did not occur in non-pregnant female mice that had undergone MIA, indicating that pregnancy is an important factor. The authors also showed that specific bac- Solid tumour Leukaemia clonal haematopoiesis. Extrinsic influences such as chemotherapy and radiation therapy, although aimed at keeping solid tumours at bay, might also cause mutations that enhance the fitness of clonal HSCs. In doing so, they could actually contribute to solid-tumour progression (Fig. 1) , by providing microenvironmental cues that act to promote the fitness of solid-tumour stem cells. This will need to be investigated in further studies.
It is possible that the mutations observed by Coombs et al. in PPM1D and some other genes are germline (inherited) mutations, and so are present in all cells of the body, rather than arising specifically in HSCs. However, a major contribution of germline mutations to clonal haematopoiesis, which usually emerges with advanced age, seems unlikely. Moreover, the association between clonal haematopoiesis during ageing and the development of leukaemia suggests that these mutations are drivers of cancer, rather than passengers, again arguing against a germline origin. Nonetheless, the functional contribution of inherited mutations to clonal haematopoiesis and tumour progression has not been fully explored and should be addressed in future.
Clonal haematopoiesis has been thought of as caused mainly by DNA mutations acquired during ageing 9, 10 . But equally important might be ageing-associated disruption of RNA processing. Such disruption induces a loss of normal human HSC dormancy, survival and self-renewal, and thus reduces overall HSC fitness 11 . In addition to these cell-intrinsic injuries to DNA and RNA, mutations in both molecules can be induced during ageing by extrinsic inflammatory signalling molecules and metabolic dysfunction [12] [13] [14] [15] [16] . These factors, too, might enhance clonal haematopoiesis and the development of both blood-related and solid tumours.
As a body of work, research into clonal haematopoiesis is shedding light on the fuel that feeds cancer. Perhaps by understanding that we cannot always eradicate tumours without correcting the 'bad blood' within them, we will be able to devise more-effective cancer eradication strategies. ■
